QIAGEN delivers solid Q4 2024 growth ahead of outlook
QIAGEN reported solid Q4 2024 performance with net sales of $521 million (+2% actual rates, +4% CER core growth). Q4 highlights include net sales of $525 million CER exceeding the $520 million outlook and adjusted diluted EPS of $0.61 surpassing guidance. The adjusted operating income margin improved to 30.6%, up 2.6 percentage points from Q4 2023.
Key products QIAstat-Dx, QuantiFERON, and QIAcuity maintained double-digit growth. For full-year 2024, the company exceeded sales and adjusted EPS outlook, with free cash flow increasing 63% to $506 million. The 2025 outlook projects about 4% CER sales growth (5% CER core sales growth) and adjusted diluted EPS of at least $2.28 CER, targeting adjusted operating income margin improvement of at least 150 basis points.
The company returned approximately $300 million to shareholders in January through a synthetic share repurchase.
QIAGEN ha riportato una solida performance nel quarto trimestre del 2024, con vendite nette di 521 milioni di dollari (+2% ai tassi attuali, +4% di crescita core a tassi costanti). I punti salienti del quarto trimestre includono vendite nette di 525 milioni di dollari a tassi costanti, superando le previsioni di 520 milioni di dollari, e un utile per azione diluito rettificato di 0,61 dollari che supera le stime. Il margine dell'utile operativo rettificato è migliorato al 30,6%, con un aumento di 2,6 punti percentuali rispetto al quarto trimestre del 2023.
I principali prodotti QIAstat-Dx, QuantiFERON e QIAcuity hanno mantenuto una crescita a doppia cifra. Per l'intero anno del 2024, l'azienda ha superato le previsioni di vendita e di utile per azione rettificato, con un flusso di cassa libero in aumento del 63%, raggiungendo 506 milioni di dollari. Le previsioni per il 2025 prevedono una crescita delle vendite di circa il 4% a tassi costanti (5% di crescita delle vendite core a tassi costanti) e un utile per azione diluito rettificato di almeno 2,28 dollari a tassi costanti, puntando a un miglioramento del margine dell'utile operativo rettificato di almeno 150 punti base.
L'azienda ha restituito circa 300 milioni di dollari agli azionisti a gennaio attraverso un riacquisto di azioni sintetiche.
QIAGEN reportó un sólido desempeño en el cuarto trimestre de 2024, con ventas netas de 521 millones de dólares (+2% a tasas actuales, +4% de crecimiento core a tipos constantes). Los destaques del cuarto trimestre incluyen ventas netas de 525 millones de dólares a tipos constantes, superando las proyecciones de 520 millones de dólares, y un beneficio por acción diluido ajustado de 0,61 dólares que supera la guía. El margen de ingresos operativos ajustados mejoró al 30,6%, un aumento de 2,6 puntos porcentuales en comparación con el cuarto trimestre de 2023.
Los productos clave QIAstat-Dx, QuantiFERON y QIAcuity mantuvieron un crecimiento de dos dígitos. Para el año completo de 2024, la compañía superó las proyecciones de ventas y de BPA ajustado, con flujo de caja libre aumentando un 63% hasta 506 millones de dólares. Las proyecciones para 2025 prevén un crecimiento de ventas de alrededor del 4% a tipos constantes (5% de crecimiento de ventas core a tipos constantes) y un BPA diluido ajustado de al menos 2,28 dólares a tipos constantes, apuntando a mejorar el margen de ingresos operativos ajustados en al menos 150 puntos base.
La compañía devolvió aproximadamente 300 millones de dólares a los accionistas en enero a través de una recompra de acciones sintéticas.
QIAGEN은 2024년 4분기에 5억 2천1백만 달러의 견고한 실적을 보고하며 (+2% 현재 환율, +4% 고정 환율에서의 핵심 성장). 4분기 하이라이트로는 5억 2천5백만 달러의 고정 환율 판매가 5억 2천만 달러의 전망을 초과했으며, 조정된 희석 주당순이익(EPS)이 0.61달러로 가이던스를 초과했습니다. 조정된 운영 소득 마진은 30.6%로 향상되어, 2023년 4분기 대비 2.6% 포인트 증가했습니다.
주요 제품인 QIAstat-Dx, QuantiFERON, QIAcuity는 두 자릿수 성장률을 유지했습니다. 2024년 전체 연도에 대해, 회사는 판매 및 조정된 EPS 전망을 초과 달성했으며, 자유 현금 흐름은 63% 증가하여 5억 6천만 달러에 이릅니다. 2025년 전망은 약 4%의 고정 환율 판매 성장(5% 고정 환율 핵심 판매 성장)과 최소 2.28달러의 조정된 희석 EPS을 예상하며, 조정된 운영 소득 마진을 최소 150베이시스 포인트 개선할 것을 목표로 하고 있습니다.
회사는 1월에 약 3억 달러를 합성 주식 매입을 통해 주주에게 환원했습니다.
QIAGEN a rapporté une solide performance au quatrième trimestre 2024, avec des ventes nettes de 521 millions de dollars (+2% aux taux actuels, +4% de croissance core à taux de change constant). Les faits marquants du quatrième trimestre incluent des ventes nettes de 525 millions de dollars à taux de change constant, dépassant la prévision de 520 millions de dollars, et un BPA dilué ajusté de 0,61 dollar, surpassant les prévisions. La marge d'EBIT ajustée s'est améliorée à 30,6%, soit une augmentation de 2,6 points de pourcentage par rapport au quatrième trimestre 2023.
Les produits clés QIAstat-Dx, QuantiFERON et QIAcuity ont maintenu une croissance à deux chiffres. Pour l'année 2024, l'entreprise a dépassé les prévisions de ventes et de BPA ajusté, avec un flux de trésorerie libre en hausse de 63% à 506 millions de dollars. Les prévisions pour 2025 projettent une croissance des ventes d'environ 4% à taux de change constant (5% de croissance des ventes core à taux de change constant) et un BPA dilué ajusté d'au moins 2,28 dollars, visant à améliorer la marge d'EBIT ajustée d'au moins 150 points de base.
L'entreprise a retourné environ 300 millions de dollars aux actionnaires en janvier par le biais d'un rachat d'actions synthétiques.
QIAGEN berichtete über eine solide Leistung im vierten Quartal 2024 mit Nettoumsätzen von 521 Millionen Dollar (+2% zu aktuellen Kursen, +4% Kernwachstum bei konstanten Wechselkursen). Die Highlights des vierten Quartals umfassen Nettoumsätze von 525 Millionen Dollar bei konstanten Wechselkursen, die die Prognose von 520 Millionen Dollar übertreffen, sowie einen bereinigten verwässerten EPS von 0,61 Dollar, der die Erwartungen übertrifft. Die bereinigte operative Gewinnmarge verbesserte sich auf 30,6%, was einem Anstieg von 2,6 Prozentpunkten im Vergleich zum vierten Quartal 2023 entspricht.
Wichtige Produkte QIAstat-Dx, QuantiFERON und QIAcuity wiesen ein zweistelliges Wachstum auf. Für das Gesamtjahr 2024 hat das Unternehmen die Verkaufsprognosen und den bereinigten EPS übertroffen, wobei der freie Cashflow um 63% auf 506 Millionen Dollar gestiegen ist. Die Prognosen für 2025 gehen von einem Verkaufswachstum von etwa 4% bei konstanten Wechselkursen (5% Kernvertriebswachstum bei konstanten Wechselkursen) und einem bereinigten verwässerten EPS von mindestens 2,28 Dollar aus, mit dem Ziel, die bereinigte operative Gewinnmarge um mindestens 150 Basispunkte zu verbessern.
Das Unternehmen hat im Januar etwa 300 Millionen Dollar an die Aktionäre durch einen synthetischen Aktienrückkauf zurückgegeben.
- Q4 2024 net sales exceeded outlook at $525 million CER
- Adjusted operating income margin improved by 2.6 percentage points to 30.6%
- Free cash flow increased 63% to $506 million
- QIAstat-Dx secured four FDA clearances in 2024
- QuantiFERON achieved 11% CER growth in 2024
- Lower non-operating income contributions expected in 2025
- Challenging instrument purchase trends affecting QIAcuity segment
Insights
QIAGEN's Q4 performance demonstrates impressive operational execution and strategic positioning. The 30.6% adjusted operating margin, up 260 basis points year-over-year, reflects successful efficiency initiatives and portfolio optimization, particularly following the NeuMoDx discontinuation. This margin expansion while maintaining investment in growth initiatives signals strong operational leverage.
The 85%+ recurring revenue base provides exceptional visibility and stability, a important differentiator in the life sciences tools sector. This recurring component, primarily from consumables and assays, creates a razor/razor-blade model that supports sustainable growth and profitability.
Key growth drivers show strong momentum:
- QIAstat-Dx secured 4 FDA clearances in 2024 and achieved 660+ placements, expanding the installed base for future consumables growth
- QuantiFERON's 11% CER growth and 60% untapped market in TB testing indicates substantial runway
- QIAcuity's clinical market expansion diversifies the digital PCR opportunity beyond research
The $506M free cash flow (+63% YoY) and $300M shareholder return through synthetic share repurchase demonstrate strong cash generation and disciplined capital allocation. The 2025 outlook for 150+ bps margin improvement while absorbing lower non-operating income shows confidence in operational excellence initiatives.
-
Q4 2024: Net sales of
$521 million 2% actual rates, +4% constant exchange rates (CER) core growth); diluted EPS of$0.39 $0.61 -
Net sales of
$525 million $520 million $0.61 $0.60 - QIAstat-Dx, QuantiFERON and QIAcuity digital PCR continue double-digit growth pace
-
30.6% adj. operating income margin up 2.6 percentage points vs.28.0% in Q4 2023
-
Net sales of
-
FY 2024: Exceeded outlook for sales and adj. EPS; adj. operating income margin improves 1.8 percentage points to
28.7% -
Free cash flow rises
63% to$506 million
-
Free cash flow rises
-
2025 outlook for about
4% CER sales growth (about +5% CER core sales growth) and adj. diluted EPS of at least$2.28
VENLO,
Net sales for Q4 2024 increased
QIAGEN expects the solid growth pace in H2 2024 to continue in 2025. Net sales are expected to rise about
“Our teams at QIAGEN concluded 2024 with a solid performance in the fourth quarter, exceeding our outlook for net sales and profitability. These results underscore the resilience of our portfolio, with over
“Our solid sales growth in the second half of 2024 mirrors our plans for further strong growth in 2025 as we reconfirm our 2028 targets. QIAstat-Dx exceeded expectations with four FDA clearances for our syndromic testing system in 2024 and one already in 2025, coupled with over 660 placements in 2024 that was ahead of our target. QuantiFERON delivered
“We are pleased with our 2024 results that featured strong free cash flow combined with solid sales growth and a significant increase in the outlook for adjusted EPS during the year thanks to operational profitability improvements. Our confidence in QIAGEN's future is reflected in the return of about
Please find a PDF of the full press release incl. tables here.
Investor presentation and conference call
A conference call is scheduled for Thursday, February 6, 2025, at 16:00 Frankfurt Time / 15:00 London Time / 10:00 New York Time. A live audio webcast will be accessible in the investor relations section of the QIAGEN website (www.qiagen.com), with a recording available after the event. The presentation will be published ahead of the call in this section: QIAGEN Investor Relations - Events and Presentations.
Use of adjusted results
QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) basis, along with other non-
About QIAGEN
QIAGEN N.V., a
Forward-Looking Statement
Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the
Source: QIAGEN N.V.
Category: Financial
View source version on businesswire.com: https://www.businesswire.com/news/home/20250205648400/en/
Investor Relations
John Gilardi
+49 152 018 11711
Domenica Martorana
+49 152 018 11244
e-mail: ir@QIAGEN.com
Public Relations
Thomas Theuringer
+49 2103 29 11826
Lisa Specht
+49 2013 29 14181
e-mail: pr@QIAGEN.com
Source: QIAGEN N.V.
FAQ
What were QIAGEN's (QGEN) Q4 2024 financial results?
How much free cash flow did QIAGEN (QGEN) generate in 2024?
What is QIAGEN's (QGEN) sales growth outlook for 2025?
How much did QIAGEN (QGEN) return to shareholders in January 2025?
What was QIAGEN's (QGEN) QuantiFERON growth rate in 2024?
